Search Results

CytoSorbents Corporation announces the regulatory approval of CytoSorb® in Taiwan by the Taiwan Food and Drug Administration (TFDA).

TLC BioSciences announced that the Abstract Selection Committee of the American College of Rheumatology has accepted TLC’s late-breaking abstract on TLC599 for oral presentation at ACR Convergence 2023.

TLC BioSciences announced that the company will present at the 42nd Annual JP Morgan Healthcare Conference at 2:00pm PT on Tuesday, January 9, 2024.

OrsoBio, Inc., a clinical-stage biopharmaceutical company developing treatments for obesity and obesity-associated disorders, today announced new data for liver-targeted mitochondrial protonophore TLC-6740 being presented at the 84th Scientific Sessions of the American Diabetes Association being held June 21-24, 2024, in Orlando, Fla.

TLC BioSciences announced that it has entered a commercialization agreement with Endo International plc for rights in the United States to TLC599, a proprietary BioSeizer® sustained release injectable in Phase 3 development for the treatment of osteoarthritis pain.

Co-Diagnostics, Inc. announced that the Company will be hosting a booth and delivering a presentation at the 9th Asia Pacific Region Conference of the International Union Against Tuberculosis and Lung Disease on April 26-29, 2024 in Taipei, Taiwan.